Sunday, March 14, AstraZeneca Plc reviewed safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.
The review which covered more than 17 million people vaccinated in the UK and European Union, comes after health authorities in some countries suspended the use of its vaccine over clotting issues.
According to the company, “A careful review of all available safety data of more than 17 million people vaccinated in the European Union and the UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country.”
15 events of deep vein thrombosis and 22 events of pulmonary embolism have been reported so far, which is similar across other licensed COVID-19 vaccines, the drugmaker said.
The company said additional testing has and is being conducted by the company and the European health authorities and none of the re-tests have shown cause for concern. The monthly safety report will be made public on the EMA website in the following week, AstraZeneca said.